Artificial intelligence companies are increasingly putting resources into health care and drug discovery as a way to improve their public image and broaden revenue streams. The move helps explain why firms that face criticism over environmental impact or rising utility costs are promoting ambitions to contribute to medical breakthroughs.
Concrete developments
-
The Wall Street Journal reported this month that Anthropic is emphasizing biology and health care to bolster investor confidence ahead of a large initial public offering. Anthropic CEO Dario Amodei wrote on X that the company is "moving quickly in biology and medicine," and expects "incredible results in the coming years and some early glimmers in the coming months."
-
Nvidia and Eli Lilly are creating a $1 billion drug‑discovery lab in San Francisco to pair life‑science researchers with AI modelers and engineers.
-
Isomorphic Labs, a spinoff from Google focused on AI drug discovery, raised $2.1 billion to hire more AI and clinical talent and has active research collaborations with Novartis, Eli Lilly, and Johnson & Johnson.
Potential benefits and clear limitations
AI is accelerating aspects of drug development and assisting clinicians with imaging analysis and diagnostics. However, the technology also brings tradeoffs:
- Real scientific breakthroughs may still be years away, which undercuts quick public reassurances.
- AI tools and related software can increase health‑care costs by producing more detailed documentation and adding layers of service.
- There are security concerns: AI‑enabled research tools could be repurposed for harmful ends, including the potential development of biological weapons.
Anthropic put strict safeguards on its next‑generation Claude Fable 5 model after concluding the system could provide a "significant uplift" to a bad actor.
Political and social friction
The push into life sciences coincides with frontier AI labs preparing for public listings to finance the enormous expense of training new models and running multi‑gigawatt computing infrastructures. Lloyd Price, a partner at Nelson Advisors, frames health‑care investments as both revenue diversification and a "hearts‑and‑minds" play: demonstrable medical advances could change public perception of AI from an environmental and security concern into something like a critical public utility.
Still, several challenges remain:
- Local opposition: parts of the U.S. public have adopted a NIMBY stance toward data centers, with moratoria, threatened lawsuits, and worries about job displacement.
- Political posture: the Trump administration is taking a relatively hands‑off regulatory approach while still maintaining oversight of safety and privacy, creating a delicate balance with industry.
- Distrust of large drug companies: the public often blames big pharma for high drug prices, and an AI company might face backlash if it appears to prioritize profits over patient affordability.
Bottom line
AI labs will need to show measurable societal benefits, not just placate investors. Whether the public will accept more server farms and the attendant risks in exchange for potential medical gains remains unsettled. As Lloyd Price noted, drug discovery is a team sport and AI is only one player — when and how much AI will directly lead to new drugs is still an open question.
